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Abstract
Tyrosine kinase inhibitors are taking up an increasingly significant role in 
treating cancers. There are different types of TKIs currently used in clinical set-
tings. However, TKI-associated limitations such as resistance and adverse effects are 
frequently reported. In this chapter, we would comprehensively review the clinical 
efficacy of current TKIs using the currently available clinical trial data. Significant 
limitations of TKIs on cancer treatment will be further summarized and discussed. 
The strategies on overcoming the limitations of TKIs to maximize their clinical 
effectiveness and efficiency, such as complementary use of Chinese medicine or 
development of novel TKIs, will be proposed. In conclusion, an overall picture of 
the clinical use and limitation of the current TKIs will be drawn and the prospective 
development in overcoming the limitations will be discussed. Evaluation of clinical 
efficacy of TKIs, evaluation of limitations of TKIs, strategies in overcoming the 
limitations of TKIs, and conclusion (including prospective development of TKIs) 
are discussed below.
Keywords: tyrosine kinase inhibitors, targeted therapy, cancer management, 
clinical efficacy, limitations, future strategies
1. Introduction
The development of tyrosine kinase inhibitors (TKIs) is revolutionary in 
treating cancers, as they act much more specifically toward malignant cells when 
compared to conventional cytotoxic chemotherapy [1]. In the past two decades, 
a plenty of novel compounds under this category have been discovered and are 
taking up an increasingly significant role in cancer treatment, especially for 
metastatic carcinomas. Many are proven with great efficacy. They showed sig-
nificantly better results in progress-free survival rate with fewer side effects [1]. 
Looking back at the short but eventful history of this drug class, this book chapter 
intends to do an evaluation on clinical efficacy and effectiveness of TKIs, basing 
on the currently available clinical trial data. Significant limitations of TKIs on 
cancer treatment will be further summarized and discussed. Finally, strategies in 
overcoming the limitations will be proposed. With an overall picture of clinical 
use and limitations of current TKIs, prospective developmental directions will 
then be discussed.
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Tyrosine kinases are a subclass of protein kinases, which are enzymes that cata-
lyze the transfer of gamma phosphate group from a nucleoside triphosphate donor 
(e.g., ATP) to targeted proteins, hence resulting in a conformational change of the 
protein, which alters its function [2]. Tyrosine kinases are frequently involved in 
the cellular response to various growth factors, cytokines, and hormones (e.g., EGF, 
PDGF, VEGF, ABL, and JAK) [3, 4]. These molecules are, in many cases, responsi-
ble for the various mechanisms of tumor growth such as cell growth, cell prolifera-
tion, stromal growth, angiogenesis, and tissue invasion [4, 5]. In neoplasms, there 
are often gene mutations resulting in activation of the above pathways [6, 7]. It 
could be an excessive expression of growth factors/hormones, an excessive expres-
sion of their receptors (i.e., increased sensitivity to receptor tyrosine kinases), or 
intrinsic activation of tyrosine kinases receptors, etc. [7]. Thus, by inhibiting them, 
we may be able to control or even regress tumor growth.
Tyrosine kinases inhibitors (TKIs) inhibit these growth factor signaling pathways 
by various mechanisms. They compete with ATP, substrate or for sites for dimeriza-
tion, and could also act allosterically [8]. By targeting these mutated pathways, TKIs 
are able to act specifically to cells with malignant changes and disrupt their malig-
nant growth without causing much disturbance to other physiological functioning.
Imatinib was the first tyrosine kinase inhibitor developed, and also the first to 
be approved by the U.S. Food and Drug administration (FDA) in May 2001. It was 
approved initially for the use on patients with chronic myeloid leukemia. Shortly 
after, other tyrosine kinase inhibitors are discovered. There are currently at least 
26 FDA-approved tyrosine kinase inhibitors [9] and more going down the pipe-
line. TKIs were initially only used as second-/third-line therapies, but nowadays, 
it is increasingly used as primary therapy, especially in selected patients with 
known mutations.
Tyrosine kinase inhibitors can be classified according to their acting target [10]. 
Major target classes include BCR-ABLTKIs (e.g., imatinib, dasatinib, and nilotinib), 
EGFR TKIs (e.g., gefitinib and erlotinib), and VEGFR TKIs (e.g., sunitinib and 
sorafenib) [10]. Another way to classify them would however be according to their 
generations. There are up to three, and even four, generations of TKIs. They differ 
not only by the period they are discovered, but also by their working mechanisms. 
The first-generation TKIs (e.g., imatinib and gefitinib) are reversible/competitive 
inhibitors (mostly ATP-competitive inhibitors) and are mostly single-targeted, 
whereas the second-generation TKIs (e.g., afatinib and dasatinib) and other newer 
generations of TKIs (e.g., osimertinib) are mostly irreversible/covalent binding and 
multitargeted [11]. Comparison of approaches used in first and newer generations 
will be made in later sections.
When compared to traditional chemotherapy and radiation therapy, which 
simply targets fast-growing cells, TKIs, along with many other targeted drugs, have 
a much higher specificity toward tumor cells. Thus, they provide a broader thera-
peutic window with less general toxicity. They are taking up a large role in treating 
cancers by showing significant improvements in progression-free survival rate and 
tolerability in patients.
2. Evaluation of clinical efficacy/effectiveness of TKIs
Numerous studies have been conducted to evaluate the clinical efficacy and effec-
tiveness of TKIs. Different TKIs are found to have different clinical performances on 
different cancers. Most of them showed significant efficacy, especially in improving 
progression-free survival (PFS), when used as first-line or non–first-line therapies. 
Therefore, a lot of studies are trying to expand the use of these TKIs to other 
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cancers, yet results are not always promising. However, overall survival was not 
improved in many cases. A lot of the studies discovered a high percentage of users 
progressing to drug resistance eventually. In the following, the clinical efficacy and 
effectiveness of a number of TKIs will be discussed individually. And in the end of 
this section, a brief comparison is drawn.
2.1 Clinical efficacy/effectiveness of first-generation TKIs
2.1.1 Imatinib (BCR-ABL TKIs)
Imatinib is an orally administered small molecule tyrosine kinase inhibitor, 
which inhibits tyrosine kinases, specifically BCR-ABL, c-KIT, and PDGFRA [12]. 
Its marketing name is Gleevec (USA) or Glivec (Europe/Australia), also referred 
to as CGP57148B or STI571 in some literature [13]. It was invented in 1990s and 
first approved by FDA in 2001. It has been a huge success and was a revolutionary 
discovery in combating cancer. Up till today, Imatinib is well known for its efficacy 
with CML and GIST, and other tumors. A summary on its clinical efficacies will be 
provided as follows:
2.1.1.1 Chronic myeloid leukemia (CML)
Imatinib is first developed against chronic myeloid leukemia (CML). CML 
is characterized by the presence of a Philadelphia chromosome [14], which is a 
product of reciprocal translocation between chromosome 9 and 22. BCL-ABL 
tyrosine kinase is overexpressed in these CML patients and is a driving force for 
leukemogenesis [15]. By inhibiting the BCL-ABL tyrosine kinase, Imatinib is found 
to be able to control the disease effectively. Imatinib has proven significant clini-
cal efficacy and effectiveness, both as a single agent or in combination therapy in 
chronic phase as well as accelerated phase/blast crisis in CML.
Imatinib, as a single agent, outperformed combined chemotherapy and inter-
feron therapy with major cytogenic response induced in 87.1% (vs. 34.7%) at 
18 months [16]. Imatinib also showed significant superiority, when combined with 
chemotherapy, against the combination of interferon therapy and chemotherapy. 
In a well-known International Randomized Study (IRIS) on 1106 newly diagnosed 
CML patients, complete hematological response was induced in 95.3% patients and 
complete cytogenic response in 73.8% patients [17]. The patients have an overall 
low risk of progressing to accelerated phase/blast crisis, and overall survival rate 
at 8 years remained as high as 85% [18] exceeding the reported survival rates in all 
previous CML therapies. Other studies trying to combine imatinib with other thera-
pies, including chemotherapy and IFN, showed that MCR/CCR did tend to occur 
earlier, for example, rate of MCR at 3 months was 70% compared to 60% when 
combining imatinib with cytarabine. Yet the gap seemed to close after 12 months, 
with 84 and 83%, respectively. Combinations have however also resulted in more 
severe side effects, and are thus in general not preferred [19]. Other studies echo 
their results and have shown that imatinib in combination with chemotherapy does 
not display superiority against imatinib as a monotherapy in CML-chronic phase, 
but instead yielded more toxicity [20, 21].
Imatinib is proved effective in accelerated phase/blast crisis as well [19, 22]. 
However, there are also studies reporting that its effects are only transient, and 
can only produce palliative function to those patients at this stage [23]. Acquired 
resistance developed in a large portion of the cases treated with imatinib. Acquired 
resistance was defined as a progression of disease or loss of response with a 5- to 
10-fold increase in BCL-ABL transcripts. These patients are subsequently treated 
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with higher dosage of imatinib, or a second-generation BCR-ABL TKI. Yet, allogenic 
hematopoietic cell transplantation remains the ultimate solution.
Response rate of imatinib in unselected CML patients is high only due to the high 
occurrence (91%) of the presence of Philadelphia chromosome [24, 25]. Its clinical 
efficacy in Philadelphia chromosome negative patients is however very low.
2.1.1.2 Gastrointestinal stromal tumors (GIST)
Gastrointestinal stromal tumor is the most common neoplasm of the mesen-
chymal cells of the digestive system and is thought to arise from the interstitial 
cells of Cajal [26]. C-KIT and PDGFRA tyrosine kinase mutations are present in a 
vast majority (85%) of these tumors [27–29]. Imatinib is able to inhibit the mutant 
C-KIT and PDGFRA tyrosine kinases. Imatinib has high efficacy against GIST in 
patients with these two mutations, both as an adjuvant therapy after surgery in 
non-metastatic GISTs, and as a palliative treatment for advanced non-resectable 
GISTs. For primary resectable GISTs, recurrence rate after surgery is extremely 
high. Studies have found that adjuvant therapy of imatinib can prolong relapse 
free survival (RFS), especially in those patients with great risks of relapse [30, 31]. 
Absolute relapse rate was 19 vs. 47% in imatinib treated patients and non-treated 
patients, respectively [30, 32]. Other studies have shown that imatinib displays 
similar promising results in GISTs in advanced stages as well. Approximately 80% 
of GIST patients with advanced disease receive some benefit from imatinib therapy 
[33], with median overall survival of 57 months, compared to 18 in chemotherapy. 
Yet, a significant proportion eventually became resistant with a median time to pro-
gression of 2 years [33]. Primary resistance was found in around 12% of the patients 
[34]. It was also found that, higher dosage of Imatinib showed no superiority over 
lower dosage [35, 36]. In GIST patients, side effects arose in 99% of the case [37]. 
The most common adverse events were diarrhea (29% of patients), nausea (27%), 
eyelid edema (23%), peripheral edema (22%), muscle cramps (15%), and fatigue 
(13%) [38]. Luckily, most patients found the side effects tolerable [37].
2.1.1.3 Others
Imatinib was also approved by the FDA and has now become the first-line 
treatment for patients with Philadelphia chromosome positive acute lymphoblastic 
leukemia (Ph + ALL), which accounts for approximately 30% of all ALL cases 
[39]. Patients treated with imatinib early are found to have higher overall survival, 
event-free survival, and relapse-free survival [40]. Studies have also justified the 
efficacy of imatinib in dermatofibrosarcoma protuberans [41, 42], chronic eosino-
philic leukemia [43], systemic mastocytosis [44, 45], aggressive fibromatosis [46], 
malignant melanoma [47], AIDS-related Kaposi’s sarcoma [48], chordoma [49, 50], 
recurrent epithelial ovarian cancer [51], and anaplastic thyroid cancer [52]. The 
use of imatinib in these cancers is not yet approved, but lots of clinical trials have 
already been conducted and their use in the future is expected.
2.1.1.4 Tolerability of side effects
Clinical trials have shown that the side effects of imatinib are generally well-
tolerated by the patients. Common side effects include edema, rash, nausea, diar-
rhea, muscle cramps, and more severely, myelosuppression [53]. Luckily, most side 
effects were mild to moderate, and in more than 95% of the patients, side effects 
could be managed with standard concomitant treatments [38].
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2.1.2 Gefitinib and erlotinib (EGFR TKIs)
Gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI774) are the two first-
generation EGFR-TKIs and are used mostly against non-small cell lung cancer 
(NSCLC), which accounts for 85% of all lung cancers [54]. As competitive antago-
nists of the ATP-binding site of EGFR, gefitinib and erlotinib were approved by the 
FDA in May 2003 and November 2004, respectively. As many cancers involve the 
hyperactivity of EGFRs, numerous studies have been conducted on drug repurpos-
ing of these two TKIs.
2.1.2.1 Non-small cell lung cancer
Gefitinib and Erlotinib are most established in treating non-small cell lung 
cancer (NSCLC) and are currently the first-line treatment for EGFR-mutated 
NSCLC patients [55]. EGFR mutations are commonly found in NSCLC patients, 
particularly in Asian populations, female gender, and nonsmokers [56, 57]. EGFR 
mutations are associated with the activation of antiapoptotic pathways as well as 
proliferation induction, thus leading to uncontrolled growth of cells. Among all the 
types of NSCLC, adenocarcinoma takes up the largest proportion, and is also the 
most commonly associated with EGFR mutations. Gefitinib was initially approved 
against NSCLC, but was then withdrawn from the market due to various studies 
showing its lack of benefit in overall survival in unselected patients. However, it 
was later found that EGFR mutation is a huge positive predicting factor for drug 
response to gefitinib, and was thus approved again. Gefitinib has well established 
clinical efficacy against advanced NSCLC when compared to chemotherapy 
[58, 59]. Progression-free survival was 10.8 vs. 5.4 months and mean overall sur-
vival was 30.5 vs. 23.6 months [59]. Combination of gefitinib with chemotherapy 
showed no superiority over gefitinib monotherapy [60]. Similarly, Erlotinib showed 
significant superiority over chemotherapy in EGFR mutation positive advanced 
NSCLC (PFS 13.1 vs. 4.6 months) [61]. However, its overall survival was reported 
to be lower than that of chemotherapy (24.68 vs. 26.16 months) [62]. Erlotinib plus 
chemotherapy is superior to chemotherapy alone with an improved PFS but not OS 
[63]. A meta-analysis revealed that the efficacy between gefitinib and erlotinib are 
comparable with erlotinib reported of more adverse drug effects [64].
Clinical effectiveness in unselected NSCLC patients were low as the frequency 
of EGFR gene mutation is 47.9% in Asians but only 19.2% in Western patients 
[65]. About only 10–35% of the NSCLC patients have EGFR mutations which are 
sensitive to the EGFR TKIs [66]. Progression-free survival in rare EGFR mutations 
was also lower than that of common EGFR mutations, yet the overall survival was 
similar [67, 68].
2.1.2.2 Other
There are currently some researches conducted on the use of gefitinib and erlo-
tinib on other cancers, yet most are currently not approved yet. Gefitinib is reported 
to show effect on pancreatic cancer [69] and is approved to treat metastatic pan-
creatic cancer in combination with chemotherapy in 2005. The effects of gefitinib 
and erlotinib on other cancers are also being investigated, such as nasopharyngeal 
cancer [70], gastric cancer [71], esophageal cancer [72], cervical cancer [73], renal 
cell carcinoma [74], and hepatocellular carcinoma [75]. Yet most studies are still in 
preclinical stages, and those limited clinical trials were often with disappointing 
results.
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2.1.2.3 Tolerability of side effects
Gefitinib has better tolerability than many cytotoxic drugs [76]. Acne-like rash 
was reported as the most common side effect, others include nausea, diarrhea, 
anorexia, stomatitis, dehydration, etc. Side effects were in general well-tolerated 
and few withdraw from gefitinib due to intolerability [76]. Erlotinib is in general 
well tolerated as well. Yet it was reported to have more severe side effects than that 
of gefitinib and was more frequently involved with dosage reduction due to side 
effect intolerance [77]. Significantly higher rates and severity of skin rash, nausea, 
vomiting, fatigue, and stomatitis were also reported.
2.1.3 Sunitinib and sorafenib (VEGFR TKIs)
Sunitinib (Sutent, SU11248) and sorafenib (Nexavar) are first-generation 
VEGFR-TKIs and are well established in the use against renal cell carcinoma 
(RCC) and hepatocellular carcinoma (HCC), respectively. The VEGF family are 
frequently overexpressed in various solid tumors and bind to vascular endothe-
lium and induce angiogenesis. Sunitinib and sorafenib are both multitarget ATP-
competitive TKIs. Sunitinib inhibits tyrosine kinases such as VEGFR2, PDGFRβ, 
KIT, RET, CSF1R, and FLT3. Sorafenib inhibits tyrosine kinases including 
VEGFRs, PDGFRs, B-RAF, MEK, and ERK. They are both FDA approved for RCC, 
GIST and RCC, HCC, respectively. Their clinical efficacies are discussed below.
2.1.3.1 RCC
VEGF overexpression and high vascularization is a common feature of RCC. Both 
sunitinib and sorafenib were approved for renal cell carcinoma as first- and second-
line therapies. Sunitinib was approved for metastatic RCC (mRCC) in 2006 after 
a phase III trial showing its superiority over IFN therapy [78]. Sunitinib displayed 
well clinical efficacy and effectiveness with median OS 26.4 months and PFS 
11.0 months, especially in clear cell RCC, compared to OS 21.8 months in IFN therapy 
[78]. However, study also showed that median PFS and OS are not significantly 
different in poor-risk group [79]. Finally, a large scaled clinical trials conducted on 
unselected heterogeneous RCC patients confirmed the effectiveness of sunitinib [80]. 
Combination of sunitinib with chemotherapy was not explored after phase I trials 
showing its poor safety profile [81]. Trials combining sunitinib with other therapies 
have also shown no improved efficacy, yet increased toxicity [82]. On the other hand, 
Sorafenib was also proven to have high clinical efficacy against mRCC, both as first- 
and second-line therapy [83]. It was found to prolong PFS when compared to placebo 
after the failure of immunotherapy [84]. Yet there is no statistically significant differ-
ence in OS. Studies comparing efficacy of sunitinib and sorafenib showed no signifi-
cant difference, with sorafenib slightly superior in elderly patients [85]. Sequence of 
use of sunitinib and sorafenib also has no significant difference [86].
2.1.3.2 HCC
Preclinical studies have demonstrated that MEK and ERK pathways play a role 
in hepatocellular carcinoma [87]. VEGF pathway also plays a significant role in 
angiogenesis in HCC [88]. This provides a window of opportunity of prolonging 
survival through TKIs targeting these pathways, including sorafenib. For unresect-
able HCC, especially in cases where potential curative methods or transarterial 
chemoembolization (TACE) are not available, Sorafenib is highly recommended as 
it demonstrates high clinical efficacy [89]. Sorafenib was reported with 3 months 
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longer in median overall survival (10.7 vs. 7.9) when compared to placebo [90]. Yet 
there was no significant difference in the median progression time to symptomatic 
progression [91]. Sorafenib, when combined with chemotherapy, also showed 
superiority over chemotherapy alone, with PFS 6.0 vs. 2.7 months and OS 13.7 vs. 
6.5 months [92]. Yet it has poor effectiveness in generalized HCC patients and many 
argue that its efficacy is questionable [93].
2.1.3.3 GIST
Sunitinib is used against GIST as well and has been approved for usage following 
failure/intolerance of imatinib in 2006 [94]. The median time to progression was 
27.3 weeks compared to 6.4 weeks in placebo [95]. There was no overall survival 
benefit of sunitinib over placebo, but the results were not reliable due to crossing 
over of placebo patients to sorafenib group. Studies have been conducted to modify 
the patient selection procedure in attempt to further raise its effectiveness, but are 
all in vain [96]. On the other hand, sorafenib also showed certain efficacy toward 
GIST. Yet its efficacy was lower than that of imatinib, and was thus only used as 
third/fourth line, after failure of initial therapy [97].
2.1.3.4 Differentiated thyroid cancer (DTC)
Sorafenib is also approved for use against advanced thyroid cancer which are 
resistant to radioactive iodine. Prior to the discovery of sorafenib, there was no 
effective treatment for this group of patients and overall survival was poor [98]. 
With sorafenib, a phase III trial showed that their PFS is greatly improved when 
compared to placebo (10.8 vs. 5.8 months) and thus provides a new treatment 
option for radioactive iodine resistant advanced DTC patients [99].
2.1.3.5 Tolerability of side effects
Compared to other TKIs, the tolerability of sunitinib is lower. Adverse events 
of any grade are reported in up to 95% of patients with one-third drug inter-
ruption due to intolerability in metastatic RCC [100]. Most common grade 3/4 
adverse events include thrombocytopenia (10%), fatigue (9%), and asthenia, 
neutropenia and hand foot mouth syndrome (each 7%) [80]. It is commonly 
associated with various side effects including hypertension, hypothyroidism, 
diarrhea, fatigue, and nausea. Therefore, studies have recommended a special 
schedule for the administration for this reason, with 2-week drug use followed by 
a 1-week drug holiday alternatively, which offers a similar efficacy but with higher 
tolerability [101–103]. Sorafenib has a slightly better safety profile [104]. Safety 
profile agrees with what is previously reported, with hand–foot skin reaction 
(58.0%), lipase elevation (57.3%), and diarrhea (42.7%) as the most frequent 
drug-related adverse events. Neither unknown adverse event nor cumulative 
toxicity was observed over the long-term use of sorafenib [105]. Yet intolerability 
remains one of its greatest limitations.
2.2 Clinical efficacy/effectiveness of second-generation TKIs
2.2.1 Dasatinib, nilotinib, bosutinib, and radotinib (BCR-ABL TKIs)
Following the success of Imatinib, many second-generation TKIs targeting BCR-
ABL have also been developed. These include dasatinib, nilotinib, bosutinib, and 
radotinib, and also a few more that will not be included in this discussion, including 
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ON012380, MK0457, PHA739358, etc. They are much more potent than imatinib 
and showed promising efficacy in treating patients who have failed imatinib 
 treatment [106].
Dasatinib (Sprycel, DB01254) was the first FDA approved among them and is a 
dual Src and ABL kinase inhibitor. Besides binding to these two kinases, it also has 
inhibitory effect on PDGFRβ, c-KIT, and EPHA2 [107]. By targeting more kinases than 
those of imatinib, dasatinib is able to tackle multiple types of resistant mechanisms 
against imatinib, including secondary BCR-ABL mutation, alternative Src signaling 
pathway activation, and multidrug resistance gene overexpression. Study showed 
durable results of treatment with dasatinib following imatinib. Imatinib resistant/
intolerant patients showed early (3–6 months) complete cytogenic response and major 
molecular response, and were associated with better PFS and OS rates [108, 109]. 
When compared to imatinib as first-line treatment to newly diagnosed CML, dasatinib 
showed even better response. It was able to achieve higher percentage of complete 
cytogenic response and major molecular response with a higher rate [110].
Nilotinib (Tasigna, AMN107), on the other hand, is more structurally similar to 
imatinib, but is 20–50 folds more potent. Nilotinib was another huge success. It was 
able to induce complete hematological response in 92% of the patients who were resis-
tant/intolerant to imatinib [111]. Similarly, it was also found to be superior as first-line 
treatment than imatinib for newly diagnosed Ph + CML [112]. Both Dasatinib and 
Nilotinib are found to give similar results in large community settings as well. When 
compared to first-generation TKI imatinib, dasatinib and nilotinib performed signifi-
cantly better as first-line treatment to newly diagnosed CML patients. They achieve 
higher Complete Cytogenic Response (CCyR) or Major Molecular Response (MMR) 
at 6, 12, and 18 months, respectively. By 12 months, 61% patients achieved CCyR or 
MMR compared to only 38% treated with imatinib. Time to MMR is also significantly 
higher in dasatinib and nilotinib than imatinib [113].
Bosutinib (Bosulif, SKI606) was initially approved in CML-AP/BC, and is later 
expanded to CML-CP. Trials prove improved rates of MMR at 12 months when compared 
to imatinib (47.2 vs. 36.9%) [114]. Soon it was also used as first-line therapy against CML.
Radotinib (Supect, IY5511) also showed significant superiority over imatinib. 
With minimum 12 months follow-up, radotinib demonstrated significantly higher 
and faster rates of CCyR and MMR than imatinib in patients with newly diagnosed 
CML-CP [115].
2.2.1.1 Tolerability of side effects
The second-generation BCR-ABL TKIs seem to have significantly higher efficacy 
than imatinib. Yet, their side effects are also more severe than that of imatinib. This is 
likely due to the increased potency as well as multi-targeting of the drugs. For example, 
when comparing bosutinib to imatinib, patients taking bosutinib have higher rates of 
increased liver enzyme values (24 vs. 4%), thrombocytopenia (13.8 vs. 5.7%), neu-
tropenia (6.7 vs. 12.1%), and diarrhea (7.8 vs. <1%). 77.9% patients experienced severe 
Grade 3/4 adverse events and 24% patients had to discontinue bosutinib therapy due 
to emergence of adverse events in a study [116]. Radotinib’s side effects are also more 
severe than that of imatinib. Grade 3/4 ALT/AST elevations caused 68% dosage reduc-
tion/interruption in radotinib patients, but only 19% in imatinib patients.
2.2.2 Afatinib and dacomitinib (EGFR TKIs)
Second-generation EGFR TKIs are irreversible inhibitors and are designed to 
target other ErbB family members, including HER2, to have more potent inhibition. 
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They target not only the T790M mutation of EGFR, but also other EGFR-activating 
mutations as well as wild-type EGFR [117].
Afatinib (Gilotrif, BIBW2992) is an irreversible inhibitor for the ERBB fam-
ily, including HER1(EGFR), HER2, and HER4. Studies have proven that afatinib 
was effective in prolonging PFS when compared to chemotherapy (median PFS 
11.1 vs. 6.9 months) [118]. When compared to erlotinib, afatinib can also signifi-
cantly increase PFS by 18%, improve OS by 19% and improve disease control rate 
(51 vs. 40%) in NSCLC patients after failure of chemotherapy. It was eventually 
approved by FDA as another first-line therapy for NSCLC.
Dacomitinib (PF299804) is also an irreversible inhibitor of the ERBB family, 
including HER1(EGFR), HER2 and 4. It is currently still in the preregistration 
stage and is not approved yet in any country. Findings have shown superiority over 
gefitinib: PFS 14.7 months with dacomitinib vs. 9.2 months with gefitinib as first-
line therapy [119, 120].
Second-generation EGFR-TKIs exhibit many dose-limiting toxicities, mainly 
skin and GI toxicities, as they inhibit WT-EGFRs as well [117].
2.2.3 Pazopanib, tivozanib, axitinib, and regorafenib (VEGFR TKIs)
Pazopanib (Votrient, GW786034B) was compared to sunitinib and showed 
superiority. It was shown to significantly improve PFS when compared to placebo 
in both treatment naïve and cytokine-pretreated patients of RCC [121]. Similar to 
the first-generation VEGFR-TKIs, Pazopanib inhibits a large number of pathways, 
including VEGFR, c-KIT, FGFR, PDGFRβ. The lack of specificity accounts for 
its multiple side effects. Yet, its tolerability is higher than that of sorafenib and 
 sunitinib [122, 123].
Tivozanib and axitinib on the contrary, are well-known for their higher selectiv-
ity. Tivozanib (Fotivda, AV-951) is highly selective for VEGFR. In a study conducted 
on metastatic RCC, Tivozanib outperformed sorafenib as first-line treatment in 
prolonging PFS [124]. The study revealed that Tivozanib improved PFS in RCC by 
3 months (30%) when compared to sorafenib, yet has an inferior overall survival 
[124, 125]. For this reason, it is unable to obtain approval from FDA. It was however 
approved by the European Medicines Agency (EMA). Axitinib (Inlyta, AG13736) is 
also highly selective for VEGFR. Axitinib was proved to be better than sorafenib in 
treating RCCs by giving longer PFS (6.8 vs. 4.7 months) in pretreated patients and 
are thus approved as second-line use.
Regorafenib (STIVARGA) is approved by the FDA in 2012 for its use in 
metastatic colorectal cancer (mCRC) and GIST. Regorafenib monotherapy was 
found to significantly improve OS (6.4 vs. 5.0 months) in mCRC when compared 
to placebo following failure of standard therapy [126]. Soon after, its efficacy in 
GIST was also found. A clinical trial compared patients treated with regorafenib 
monotherapy vs. placebo after acquiring resistance against imatinib and suni-
tinib [127]. PFS was way higher in regorafenib group (4.8 vs. 0.9 months) and 
is thus approved by the FDA. OS was however not determined as the patients 
in the placebo group were crossed over to the regorafenib group after disease 
progression.
2.2.3.1 Tolerability of side effects
Their tolerability is significantly better than sorafenib, especially with tivozanib. 
Drug dosage reduction due to intolerance was 11.6% in tivozanib, but 42.8% in 
sorafenib [125].
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2.3 Clinical efficacy/effectiveness of third-generation TKIs
2.3.1 Ponatinib (BCR-ABL TKIs)
Ponatinib (Iclusig, IY5511) is a multitargeted TKI including BCR-ABL. It was 
specifically designed for T315I mutation-caused imatinib resistance. Studies have 
proven its high clinical efficacy of inducing cytogenic response in 66% CML-CP 
patients, which include all of the T315I mutation positive patients. Yet, in general-
ized CML-CP patients, ponatinib did not show significantly superior efficacy than 
the previous second- and first-generation TKIs [128]. Thus, it is suggested for 
first-line use only in the setting of detected T315I mutation, otherwise, merely as a 
second-line treatment following first- and second-generation TKIs.
2.3.1.1 Tolerability of side effects
Treatment-related side effects are moderately significant with ponatinib. 
Common adverse events include rash (47%), abdominal pain (46%), thrombo-
cytopenia (46%), headache (43%), dry skin (42%), and constipation (41%). It is 
however associated with a severe adverse event, which is arterial occlusive events 
(AOE), which occurred in a cumulative of 31% patients.
2.3.2 Osimertinib (EGFR)
Due to the limited efficacy in tackling T790M resistance of EGFR of the second-
generation TKIs, the third generation of EGFR-TKIs has been discovered. Third 
generation works significantly better against the T790M-mutated EGFR while 
sparing the wild-type EGFRs, making them very mutant selective. Various third-
generation EGFR-TKIs are currently under clinical trials, including osimertinib, 
PF06747775, YH5448, avitinib, rociletinib, etc. Of them all, osimertinib is the only 
currently approved drug.
Osimertinib (Tagrisso, AZD9291) is a very promising third-generation EGFR-
TKI. It is able to tackle gefitinib/erlotinib acquired resistance through T790M, exon 19 
and 21, which accounts for a large portion of acquired resistant cases. In a FLAURA 
study, Osimertinib was compared to first-line EGFR-TKIs (erlotinib and gefitinib) as 
first line therapy [129]. It showed significantly higher efficacy against EGFR-mutated 
patients, with PFS 18.9 vs. 10.2 months. An extra feature of osimertinib is its ability 
to penetrate the blood-brain barrier and tackle patients with brain metastasis as well. 
CNS progression was lower in patients treated with osimertinib (6 vs. 15%). There 
is not yet data available on comparing overall survival between the two, yet osimer-
tinib showed a trend of superiority. At 18 months of the FLAURA study, 83% of the 
patients in the osimertinib group were still alive vs. 71% in the first-generation EGFR-
TKI group. Most third-generation EGFR-TKIs combat the T790M EGFR resistance 
mechanism selectively. Yet, the other 50% resistant mechanisms remain a challenge.
2.3.2.1 Tolerability of side effects
Side effects of third-generation EGFR-TKIs are rather mild and tolerable. Side 
effects of Osimertinib commonly include rash, nausea, and diarrhea. Grade 3 or 4 
adverse events occurred in 24% of the patients, but only 2% of the patients required 
a dosage reduction, and only 4% discontinuation. However, there are also studies 
which disagree. In the FLAURA study, rate of permanent discontinuation due to 
adverse events of osimertinib was 13%. Yet it is still lower than that of those receiv-
ing first-generation EGFR-TKIs, which was 18% [129].
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2.4 Comparison
2.4.1 Newer generations perform better than first generation
Viewed as a whole, TKIs of the later generations tend to outperform the first 
generation in terms of efficacy. This is mainly because the newer generations tend 
to target multiple pathways and also provide a more potent irreversible inhibition. 
This allows them to be effective in both first-line setting, as well as combatting 
heterogeneous resistant mechanisms arisen. Yet, their downside is the occurrence of 
more severe side effects. The third-generation TKIs thus aim at targeting multiple 
pathways while sparing physiological functions, e.g., third-generation EGFR-TKIs. 
VEGFR-TKIs are the exceptions. Their first-generation TKIs are multitargeted, and 
their newer generation TKIs are more specific, and thus offer a higher tolerability. 
Studies on newer generations of TKIs delineate promising results on both their effi-
cacy as a potential first-line treatment and as a second-line treatment after acquired 
resistance of the initial therapy.
2.4.1.1 High efficacy but low effectiveness
Many TKIs seem to show merely improvement in progression-free survival, 
but not in overall survival rate. These include gefitinib in NSCLC [130], sunitinib, 
nilotinib and regorafenib in GIST [131], lenvatinib in differentiated thyroid cancer 
[132], and many other TKIs, regardless of whether they are of newer generations 
or not. Erlotinib even showed poorer overall survival rate than chemotherapy 
(24.68 vs. 26.16 months), despite a significantly higher progression-free survival [62]. 
The potential reasons shall be further discussed.
Response rate of TKIs are low in unselected patients. Various studies have shown 
that, in the absence of targeted mutation, targeted therapy performed worse than 
traditional chemotherapy. Presence of targeted mutation is a huge positive predicting 
factor for good tumor response [133, 134]. Response rate in unselected population is 
however high in a few cases, for example, in unselected CML patients. This is likely 
because the vast majority of them carry the same single mutation of BCR-ABL. It is 
also high in RCC for first-generation TKIs, since the first-generation VEGFR-TKIs are 
relatively nonspecific, and are able to target multiple mutation mechanisms.
3. Evaluation of limitations of TKIs
3.1 Development of resistance
The development of resistance has always been and will probably always be the 
greatest problem limiting the use of TKIs. The rate of developing acquired resistance 
(AR) is extremely high, and appears even to be inevitable in certain diseases. In 
EGFR-TKI therapy, a study showed the median time for patients developing AR is 
8–10 months, and all responding patients developed AR eventually, with the inevi-
table consequence of disease progression [135, 136]. The case with imatinib is slightly 
better; around 7–15% is found to have secondary resistance, i.e., disease progression 
following initial achievement of cytogenic response [137, 138]. And this is the reason 
why the PFS, despite longer than chemotherapy, is still not very long, with most 
ranging from a few months to at most a few years, despite their high disease response 
rate and promptness in controlling the disease. Acquiring resistance and disease pro-
gression seem almost inevitable in many cancer lines using TKIs. This phenomenon 
occurs indiscriminately in all generations of TKIs and is a huge challenge.
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The development of resistance comes in many ways, and many researches have 
been dedicated to finding out the mechanisms of resistance to TKIs. Studies have 
shown that cancer cells adapt to chronic therapy by through common mechanisms 
found include secondary mutations of target, activation of alternative signaling 
pathway, evading immune system and adaptive or cell fate changes, etc. Point muta-
tion at site coding for TK resulting in decreased affinity for the TKI remains the 
most prevalent mechanism of acquired resistance [139]. Point mutations (esp. T315I 
mutation) in CML patients are a major cause in AR toward imatinib. Occurrence 
of these mutations reduces the life expectancy of chronic phase CML patients from 
10 years to just 22 months [140]. Exon 20-T790M mutation is found in approxi-
mately half of the patients with progressed disease following initial EGFR-TKI use 
[141]. Any of the ways allow the tumor cells to regain its ability to grow and divide. 
The heterogeneity of resistance mechanisms poses huge difficulty for a single TKI to 
produce high response rate following AR to the initial TKI.
Newer generations of TKIs aimed at resolving acquired resistance toward the 
older generation TKIs. Yet, there are too many different types of resistance mecha-
nisms that could arise between different patients, as discussed. Taking NSCLC AR 
to erlotinib and gefitinib as an example, AR mechanism could be T790M missense 
mutation, other secondary mutations of EGFR, MET amplification, HER2 ampli-
fication, small cell histological transformation, etc. And up to 30% of the NSCLC 
patients with AR to first gen TKIs have unknown resistance mechanism [135]. Its 
heterogeneity makes the development of new generation TKIs, especially one with 
high tumor response, very hard.
The management of post-TKI disease progression is a new therapeutic challenge. 
The ways to overcome include using multitargeted approach, in which the TKI is 
effective against a broad spectrum of resistance mechanisms, or perform genetic 
tests and learning the specific resistance mechanism of the individual patient and 
selecting the next TKI. Details are discussed in the next session.
3.2  Complexity and redundancy in tumor pathways and between tumor 
subclones
Multiple regulatory factors and multiple signaling pathways exist within a tumor, 
and they each share a role in supporting tumor growth [142]. Many elements of 
these pathways are redundant, and contribute toward the same function. With all 
these redundancy, inhibiting one factor or one pathway will often not be sufficient in 
inhibiting tumor growth [143]. This is part of the reason for the robustness of cancer 
cells, allowing them to survive through a diversity of treatments. Take angiogenesis 
as an example. Although VEGF is the most potent stimulatory regulator of angio-
genesis, and human cancers often have an overexpression of VEGF, there are also 
many other stimulatory and inhibitory factors involved, which some are produced by 
tumor cells and some by the host cells. Therefore, simply administrating a single-
target VEGFR-TKIs may not result in significant antiangiogenic effect. Besides, some 
of the factors, including VEGF, can exist in multiple isoforms, making it even harder 
to inhibit the angiogenic process [1, 144]. Moreover, many tumors have more than 
one mutated pathways, for instance, both VEGFR and PDGFR mutation [145]. It is 
only through multitargeting and combination therapy, or targeting more upstream 
pathways, could a more significant response be brought about [143]. Simply inhibit-
ing one target is in many cases not effective enough to hinder cell growth.
With technology of next-generation sequencing of patient biopsies, it has been 
revealed that tumors contain vastly heterogeneous genetic alterations in multiple 
subclones. This is also called intratumor heterogeneity. This also includes geo-
graphical heterogeneity, in which the genetic makeup of metastatic tumors differs 
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from each other as well. As the neoplastic cells divide and undergo DNA replication, 
the clones are highly prone to genetic mutations, and the mutated cells continue 
to grow and give rise to their colony of cells. Thus within the same tumor, there 
could be multiple subclones each with their own variant of DNA makeup. This 
plays a huge role in the development of resistance toward TKIs. Heterogenic tumor 
subclones may exhibit different sensitivity toward the TKIs. Some tumors may have 
primary resistance, and with the TKI acting as the selecting pressure, the resistant 
subclones are selected and are able to continue growing. This accounts for the high 
rate of resistance toward TKIs. And research has also proven that high intratumoral 
heterogeneity predicts poorer prognosis and poorer response to treatment [146].
3.3 Poor patient selection
Low effectiveness of TKIs in studies may be due to poor patient selection. By 
knowing the mechanism of action of the TKIs, we know well that they could only 
work in a selected population of tumor cells, which contains the pharmacological 
target. They do not always work well in unselected populations. There are a certain 
portion of cancer cell lines which are innately resistant to the TKI therapy admin-
istered. In unselected NSCLC patients, only 15 in 58 in Japan and 1 in 61 in USA 
responded to the gefitinib treatment [147]. This is due to the heterogeneity of muta-
tions of the same cancer in different individuals. This occurs not only with initial 
therapy option, but also newer generations of TKIs as well as non–first-line TKIs. 
Response rates of many newly developed EGFR-TKIs, targeting at patients with AR 
to first-line TKIs, were lower than 10%. These include neratinib, whose response rate 
is 3% [148] and IPI-504, whose response rate is 4% [148]. Therefore, poor patient 
selection will greatly limit the effectiveness of TKIs. Mechanisms for patient selec-
tion must be developed in order to increase TKI effectiveness in community settings.
3.4 Antagonistic drug interaction
Many studies found that combining TKI with traditional chemotherapy showed 
no significant benefit, but rather an additive effect of toxicity, resulting in disap-
pointment. Concurrent administration may not be effective due to TKI induced 
G1 phase cell cycle arrest [149]. Although combination approach is believed to 
provide better outcome in many cases, practitioners must pay attention to antago-
nistic drug interactions in order to prevent this from limiting the effectiveness 
of TKI. Alternating administration schedule is proposed for many combination 
therapies in order to avoid this problem.
3.5 Side effects
Although TKIs are deemed to be relatively well tolerated, especially when 
compared to systemic cytotoxic chemotherapy, there are still many cases of side 
effects limiting the use of this drug. With variations from drug to drug, up to 50% 
report cases of skin toxicity and folliculitis with TKI use. EGFR TKIs display a broad 
spectrum of skin and hair adverse effects, including folliculitis, facial hair growth, 
facial erythema, paronychia, and varying forms of frontal alopecia, whereas VEGFR 
TKIs are more commonly associated with subungual splinter hemorrhages. Imatinib 
frequently causes periorbital edema. TKIs produce various hematological side effects 
(anemia, thrombocytopenia, neutropenia) and extra-hematological side effects, most 
commonly being edema, nausea, hypothyroidism, vomiting, and diarrhea. Regarding 
long-term effects, cardiac toxicity with congestive heart failure is discussed in patients 
receiving imatinib and sunitinib [150]. Adverse events have been reported in the use 
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of sorafenib against HCC, including Hand Foot Skin Reactions (HFSR), hyperbili-
rubinemia associated with heightened ALT. Adverse effects occurred in up to 40% 
of differentiated thyroid cancer patients, which are mainly hypertension, diarrhea, 
asthenia, or fatigue, nausea, decreased weight and appetite. This had resulted in 
dosage reduction despite good tumor response [151]. About 14% of the patients had 
to discontinue therapy due to intolerance of adverse events. Severity of side effects 
was found correlated with specificity of the TKIs. The newer generations are usually 
multitargeted, and thus yield more severe side effects. Luckily, third generations are 
more mutant selective, and thus showed improvement in this aspect.
3.6 Lack of follow-up and nonadherence
As TKI is a drug class that has to be administrated over a long period of time, 
the lack of follow-up during the course of treatment is a problem that could limit 
the effectiveness. In a study reporting effectiveness of TKIs in CML patients in a 
community setting, it is found that cytogenetic and molecular response monitoring 
assessments were conducted less frequently than recommended [113]. Poor monitor-
ing may result in delay in adjustments in treatment plan. On the other hand, TKIs are 
mostly administrated orally, which may pose a challenge in patient adherence. Poor 
patient compliance plays a role in increasing rates of acquired resistance to TKIs. It 
is found that, as the treatment progresses, those with higher adherence did achieve 
better results in achieving CCyR and MMR [113]. While adherence to TKIs is critical 
in achieving durable responses, it is surprising that merely 56% patients in a study of 
229 CML patients adhere to their dosage (which is defined as ³90% adherence) [113].
3.7 Financial burden on patients
There have been numerous studies conducted on cost-effectiveness of TKIs. But 
most work on merely the comparison between different TKIs or compare TKIs with 
other treatment. As TKIs are in many occasions not covered by the public health 
system, they are usually self-funded, unless the patient is covered by insurance, 
has successfully applied for external funding or is enrolled in a clinical trial. The 
average per person total cost of treatment with branded imatinib is (79,000 USD/
year) and even higher for dasatinib and nilotinib (87,000–92,000 USD/year) [152]. 
The humongous financial burden complicates the patients’ decision in drug choice. 
It may also affect their choice of continuation of treatment. Studies have shown that 
high costs of TKIs even lead to a delay in treatment for many patients with leukemia 
[153]. Some patients may resort to generic TKIs, which quality may not be always 
consistently good. For example, a study showed that generic Imatinib show subopti-
mal efficacy when compared to branded imatinib as first-line therapy in CML [154].
4. Strategies in overcoming the limitations of TKIs
Plenty studies have been coming up with all sorts of strategies in overcoming the 
limitations of TKIs. The big direction is to develop new inhibitors, use a combina-
tion approach, and improve patient selection.
4.1  Development of new inhibitors: specific approach and multitargeted 
approach
Following post-TKI disease progression, continuing the use of the initial 
TKI therapy does not improve PFS [155]. There is thus a desperate need for new 
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treatment options, or new TKIs. Various studies are working on drugs available 
for use after acquired resistance. A large number of new TKIs are working their 
way down the pipeline, in preclinical studies and clinical studies, a lot of which are 
very promising. The new inhibitors are either very specific toward a certain type of 
acquired mutation, or multitargeted to inhibit a broader spectrum of pathways, in 
order to overcome resistance.
With next-generation sequencing, we are able to identify the specific mutations 
and design molecules that specifically target them. The mutation mechanisms are 
however vast in diversity. Taking acquired resistance to imatinib in GIST as an 
example, in a study, among the 15 patients who acquired resistance to imatinib, 7 
were found with secondary mutation at the KIT target, 6 of which occurred at the 
exon 17 (three were N822K, two were D820Y and one was Y823D) [156]. Luckily 
we were also able to identify some more common ones, e.g., T790M mutation 
in EGFR-TKI AR. One of the strategies is thus to develop drugs that target these 
mutations specifically. To facilitate this, however, there should be more research on 
mechanisms of acquired resistance against TKIs in different cancers. However, this 
would also be a very costly method.
Another approach of new inhibitors, also a more practical approach, would 
be the multi-targeted approach, as well as the inhibiting of upstream pathways. 
As stated previously, the vast heterogeneity within tumor subclones and the 
redundancy of cancer cell signaling pathways poses a huge challenge for targeted 
therapies. One of the strategies regarding is to have multiple targets. Network model 
suggests that partial inhibition of multiple targets may exhibit better effect than 
complete inhibition of a single target [157]. This has been the trend in many newly 
developed drugs. Many studies agree that multi-targeted TKIs should perform bet-
ter than single-targeted ones in terms of efficacy and tumor response rate  
[145, 158–160]. When targeting a single molecule, the cancer cells can easily adapt 
and bend around the hindered pathway by activation of alternative pathways. By 
interacting with multiple targets simultaneously, it leaves less chance for cancer cells 
to do so [159, 161]. Multitargeted approach also eliminates the malignant cells faster 
as they inhibit multiple pathways, inhibiting the cancer cells at multiple levels.
Identifying convergent resistance mechanisms or targeting upstream pathways 
enables us to achieve something similar. Despite the large number of resistance 
mechanisms, a lot of them converge on reactivation of the driving pathway. For 
example, in BRAF-mutant melanomas, 89% of resistance mechanisms lie within the 
MAPK pathway [162]. Identifying these convergent resistance mechanisms could 
allow us to combat acquired resistance more effortlessly.
However, the multi-targeted approach is also with more severe adverse effects 
than the single-targeted [158]. It is thus important to be able to identify the suitable 
set of targets, which allows us to be specific enough to act selectively at the tumor cells 
only, not the normal body cells, yet not specific enough to prevent cancer cells from 
acquiring resistance too easily. Luckily, we are equipped with newer tools, including 
the network pharmacology approach, to aid us in the design of these new drugs [157].
4.2 Combination therapy
Combination approach with a similar mindset when that of developing multitar-
geted TKIs, it is believed that a combination of therapies would leave less chance for 
selection of resistant subclones, which allows the tumor to acquire resistance.
TKIs treatment could potentially combine with many different treatments. 
Many studies have already been conducted on the combination of TKIs with con-
ventional therapies, including chemotherapy, radiation therapy, interferon therapy, 
etc. A study showed that combination of standard-dose imatinib and IF-therapy 
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yielded better results than standard-dose or high-dose imatinib alone, as well as 
standard-dose imatinib combined with chemotherapy [21, 163]. Icotinib, an EGFR-
TKI is proved to improve radiosensitivity in lung cancer in vitro and in vivo, thus 
possibly allowing better radiotherapy effects [164]. They are extensively studied 
and are in many cases already put to clinical practice.
A TKI could also be combined with another TKI. For example, dual EGFR 
blockade by first and third-generation EGFR TKI combinations [165]. Or dual 
ALK and EGFR target inhibition in ALK translocated NSCLC with additional 
EGFR mutation [166]. Other ongoing clinical trials study the potential benefits of 
combining anti-angiogenic TKIs (e.g., apatinib, endostatin, and anlotinib) with 
EGFR-TKIs [167].
There are also studies proposing TKI combination with other target inhibitors 
including monoclonal antibodies. Researches are exploring possibilities of combi-
nations of brigatinib and anti-EGFR antibodies, third-generation TKIs with MEK 
inhibitors, and osimertinib with oxidative phosphorylation inhibitors etc. [165]. 
For acute lymphocytic lymphoma, a WEE1 inhibitor AZD-1775 is proven to signifi-
cantly enhance the efficacy of several tyrosine kinase inhibitors, such as imatinib, 
bosutinib, and ponatinib [168], or similarly, vitamin K1 with sorafenib in treating 
HCC [151] and antiestrogen fulvestrant with vandetanib in NSCLC.
Combination approach is promising, yet limited by potential toxicity. 
Combination of drug effects is true for both positive and side effects. Many 
studies echoed that concurrent chemotherapy and TKI therapy yielded no added 
benefits. Therefore, it is important to understand the mechanism of action of the 
two therapies and understand their interaction, thus design the best administra-
tion schedule. Taking TKIs and chemotherapy in an intercalated manner may 
reduce inhibitory drug interaction. A study compared synchronized administra-
tion and intercalated administration of the two therapies [101], and found that 
intercalated administration schedule improved PFS and OS [169]. More and more 
studies are thus conducted on the administration schedule and yielded similar 
results [63].
4.3 Wisdom from traditional Chinese medicine (TCM)
TCM has long been used to treat different cancers and are often shown with 
clinical efficacy. TCM herbs are able to stabilize tumor growth, control patient 
symptoms and alleviate side effects, and ultimately improve quality of life of 
patients [161]. Many researches are thus dedicated to discovering novel drugs by 
uncovering therapeutic potentials of various natural compounds.
Accumulating studies have been discovering tyrosine kinase inhibiting effects 
from natural compounds. Many TCM herbs contain natural compounds that are 
capable of interacting with multiple cellular targets [161]. Various molecules from 
traditional Chinese medicine are being discovered with tyrosine kinase inhibiting 
effects and these include 2-O-caffeoyl tartaric acid, emetine, rosmaricine, and 
2-O-feruloyl tartaric acid, which are potential EGFR inhibitors [170]. Another 
meta-analysis identified another 24 kinase inhibitors from TCM [171]. Network 
pharmacology enables us to discover more of such molecules and their targets 
[161]. Using natural compounds as drugs is relatively safe and exhibit less side 
effects [161].
On the other hand, complementary use of TCM has been actively discussed 
in recent years. Many recent studies have been conducted. They appear to be able 
to increase efficacy as well as reduce toxicity when combined with TKI therapy 
[161, 172]. Some studies showed that TCM work synergistically with EGFR-TKI 
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and has additional effect of alleviating TKI induced toxicity [173]. They are able to 
significantly raise overall response rates, disease control rate, 1-year survival rate, 
2-year survival rate, and improvement/stable Karnofsky Performance scores of 
tumors. Severe toxicity for rash was decreased, so were nausea, vomiting, and diar-
rhea [174, 175]. The strategy of minimizing or alleviating side effects of TKIs may be 
potential. This could help increase tolerability of patients and also reduce drug-
related adverse events and subsequent possible drug reduction and discontinuation, 
which will have a toll on TKI therapy effectiveness.
4.4 Improve patient selection
The drug effects of TKIs can be drastically different in two patients. It can 
work miracles in one, but have no effect at all in another. The genetic makeup of a 
patient’s tumor is a huge predicting value of the efficacy of the TKI. Various studies 
have shown the correspondence between genetic profiling and therapy response 
[176, 177]. Thus, it is vital to perform procedures to select the population of patients 
responsive toward the TKI. In the new era of personalized medicine, the most effec-
tive way of using TKIs to treat cancer is to consider each patient/tumor individually 
and to determine the strategy that specifically targets the consequences of altered 
genetics of the tumor. Not simply which TKI to use, but also which combination of 
TKIs and which combination of therapies.
4.5 Repeated monitoring, including repeated biopsy/ liquid biopsy
It was proposed that in order to overcome the limitation of AR in TKIs, repeated 
tumor biopsies should be done during the course of treatment. This is to give us the 
ability to spot mutations early and learn its resistance mechanism, thus allowing inter-
vention prior to standard detection of radiographic signs of progression. The specific 
agent/combination against that particular resistance mechanism can thus be selected.
Yet multiple resistance mechanisms within a single patient, especially between 
multiple lesions in a patient, pose challenges for biopsy. Besides, biopsies are not acces-
sible for all tumors and are also invasive to the patient. Studies have proposed repeated 
liquid biopsies as a solution [178]. Liquid biopsy checks for tumor DNA circulating 
in the blood, which is shed into the bloodstream by tumors all around the body, thus 
allowing us to peer into the tumor genome in distinct subclones in different meta-
static lesions within the patient. It is more effective in learning the heterogeneity and 
multiple resistance mechanisms than performing a single lesion biopsy. It being less 
invasive (a simple blood draw will suffice), also allows a more frequent sampling.
4.6 Improve patient compliance
Patient compliance does make a big difference in treatment outcome. Studies 
have proven that those with higher adherence did achieve better results in achiev-
ing CCyR and MMR [113]. Since many TKIs are orally administered, of long-term 
usage, and in some cases, self-administered in an out-patient setting, patient 
compliance could pose a serious challenge, especially with irregular drug schedule, 
such as one with drug holidays. Patient education is one of the ways we could 
improve patient compliance. Perhaps systems for patient monitoring could also be 
developed, including system like DOTs therapy for TB patients, where out-patients 
are required to come to the clinic and take the medicine in front of the healthcare 
workers and official record is made. Other suggestions include designing phone 
apps for patients to keep track of their drug schedule.
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4.7 Generic drug use
Generic drug use could be a possible solution to high cost of TKIs [179]. 
Researches on generic versions of various drugs have been conducted [180]. Studies 
have shown that generic imatinib and Brand named imatinib (Gleevec) showed no 
difference in efficacy [181]. Aside from imatinib, many TKIs are currently available 
in generic form, including dasatinib and sorafenib. Yet the quality of generic drugs 
is not always certified and has to be judged case by case.
4.8 Exploring the potential of TKI therapy termination
Many TKIs are believed to be required to be administered a lifetime. This has 
posed certain difficulties, including inconvenience to the patients, accumulative 
side effects, financial burden to the hospital and patient etc. Many studies are thus 
working on the possibility of discontinuing TKI therapy after a certain response is 
achieved. Some researches have identified specific subsets of patient populations 
which could consider discontinuation of TKIs [182].
5. Conclusion
Although TKIs have a very high clinical efficacy upon initial administration, the 
frequency of acquired resistance is too high, making it not as effective in improving 
overall survival. There are however many ways we can resort to, in order to prolong 
the period of stable disease, before progression. These include using multi-targeted 
approaches, or combination approaches, although it is also accompanied with 
more severe side effects. Resorting to natural compounds, for example, those from 
TCM, could be a potential way. They are often multitargeted and not as potent, thus 
allowing multitarget inhibition without bringing about severe toxicities. Adequate 
monitoring of disease status and patient adherence is another simple yet effective 
way to improve the performance of TKIs. Being able to make timely adaptations to 
treatment plan can play a vital role in prolonging survival. Another direction would 
be to place more emphasis on patient selection. There are many factors that could 
help us predict the patient’s sensitivity and response toward that TKI. TKI should 
not be used as an empirical treatment, which would be too cost-ineffective. Even for 
the same cancer same stage, the specific genetic constitution of each tumor differ 
from each other, and choice of TKI may vary dependently. Hence, personalized 
treatment is the key.
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